| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2018-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_858cff64e4565e4022fafecfe00edbd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd5cc5986b0bf0263010d1251dc03804 |
| publicationDate |
2020-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10761091-B2 |
| titleOfInvention |
Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
| abstract |
Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 μg/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874677-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11622969-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667720-B1 |
| priorityDate |
2013-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |